Molecular genetic analysis in the pathologic evaluation of solid tumors: Theory and practice

Journal of Clinical Laboratory Analysis

Volumn 11, Issue 1, 1997, Pages 10-16

  Visscher, Daniel W ^a,b   Sarkar, Fazlul H ^a   Crissman, John D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

BREAST CARCINOMA; CANCER STAGING; HUMAN; MOLECULAR GENETICS; PATHOLOGY; PROGNOSIS; REVIEW; SOLID TUMOR; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, P53; GENETIC MARKERS; HUMANS; MALE; MUTATION; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS;

EID: 0031025303     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1997)11:1<10::AID-JCLA3>3.0.CO;2-O     Document Type: Review

References (40)

1. Stephenson CF, Bridge JA, Sandberg AA: Cytogenetic and pathologic aspects of Ewing's sarcoma and neuroectodermal tumors. Hum Pathol 23:1270-1277, 1992.
2. Diffin F, Porter H, Mott MG, Berry PJ, Brown KW: Rapid and specific diagnosis of t(11;22) translocation in paediatric Ewing's sarcoma and primitive neuroectodermal tumours using RNA-PCR. J din Pathol 47:562-564, 1994.
3. Gerald WL, Ladanyi M, de Alava E, Rosai J: Desmoplastic small round-cell tumor: A recently recognized tumor type associated with a unique gene fusion. Adv Anat Palhol 2:341-345, 1995.
4. Scrable H, Wine D, Shimada, Seemayer T, Sheng WW, Soukup S, Koufos A, Houghton P, Lampkin B, Lavenee W: Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1:23, 1989.
5. Pieretti M, Powell DE, Gallion HH, Case EA, Conway PS, Turker MS: Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 26:393-397, 1995.
6. Sandberg AA: Chromosomes and hereditary predisposition to cancer. Heme Oncol Ann 2:141, 1994.
7. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC: LOH on chromosome 14q is associated with invasive but not metastatic breast cancer. Mod Pathol 9:22A, 1996 (abst).
8. Wood DP, Banks ER, Humphreys S, Rangnekar VM: Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 42:505-511, 1994
9. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, Coombes RC: Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow up. Eur J Cancer 27:1552-1555, 1991.
10. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43:765-775, 1994.
11. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332:429-435, 1995.
12. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102-105, 1992.
13. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992.
14. Eyfjörd JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ögmundsdottir HM, Anamthawat-Jonsson K: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646-651, 1995.
15. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Mercus JN, Schwartz L, Chen LC, Mayal BH: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992.
16. Battifora H: p53 immunohistochemistry:A word of caution. Hum Pathol 25:435-437, 1994.
17. Wynford-Thomas D: p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 166:329-330, 1992.
18. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited! J Pathol 172:1-4, 1994.
19. Xu L, Chen Y-T, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ, Garin-Chesa P: Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 3:83-92, 1994.
20. Jacquemier J, Molès, Penault-Llorca F, Adèlaide J, Torrente M, Viens P, Birnbaum D, Theillet C: p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results. Br J Cancer 69:846-852, 1994.
21. Baas IO, Mulder J-WR, Offerhaus GJA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12, 1994.
22. Lambkin HA, Mothersill CM, Kelehan P: Variations in immunohistochemical detection of p53 protein Overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 172:13-18, 1994.
23. Lane DP: On the expression of the p53 protein in human cancer. Mol Biol Rep 19:23-29, 1994.
24. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroseder JJ, Wold LE, Kovach JS: Pattern of p53 gene mutations in breast cancers of women in the midwestern United States. J Natl Cancer Inst 84:246-252, 1992
25. Tsuda H, Hirohashi S: Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 57:498-503, 1994.
26. Shiao Y-H, Chen VW, Scheer WD, Wu XC, Correa P: Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55:1485-1490, 1995.
27. Merlo GR, Bernardi A, Diella F, Venesio T, Cappa APM, Callahan R, Liscia DS: In primary human breast carcinomas mutations m exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int J Cancer 54:531-535, 1993.
28. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC Nakamura Y, White R: Allelotype of colorectal carcinomas. Science 24:207-211, 1989.
29. Grignon DJ, Hammond EH: College of American pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the prostate cancer working group. Arch Pathol Lab Med 119:1122-1126, 1995.
30. Vogelstein B, Kinzler KW: Has the breast cancer gene been found? Cell 79:1-3, 1994.
31. Wiggs J, Nordenskj_ld M, Yandell D, Rapaport J, Grondin V, et al: Prediction of the risk of hereditary retinoblastoma, using DNA polymorphisms within the retinoblastoma gene. N Engl J Med 318:151-157, 1988.
32. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y: Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 53:3382-3385, 1993.
33. Borg A, Zhang Q-X, Johannsson O, Olsson H: High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. J Natl Cancer Inst 86:792-794, 1994.
34. Miki Y, Swensen J, Shattuck-Eidens D, Futreal A, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 266:66-69, 1994.
35. Nowak R: Many mutations may make test difficult. Science 266: 1470, 1994.
36. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11:1-3, 1995.
37. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 55:1002-1005, 1995.
38. Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL: Genetic counseling for families with inherited susceptibility to breast and ovarian cancer JAMA 269:1970-1974, 1993.
39. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038, 1993.
40. Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia-telangiectasia. JAMA 325(26):1831-1836, 1991.